CG Oncology (CGON) Gains from Investment Securities (2023 - 2026)
CG Oncology (CGON) reported Gains from Investment Securities of $174000.0 for Q1 2026, down 79.74% on a YoY basis from $859000.0 in Q1 2025, and up 291.21% quarter-over-quarter from -$91000.0 in Q4 2025.
CG Oncology (CGON) Gains from Investment Securities (2023 - 2026) Analysis & Trends
CG Oncology has reported Gains from Investment Securities for 4 years, with the latest figure at $174000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 79.74% year-over-year to $174000.0; the trailing twelve-month figure through Sep 2025 stood at $94624.0 (down 98.77% YoY), and the FY2025 full-year result was $8.0 million, up 21.05% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $174000.0, up from -$91000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $9.0 million in Q2 2025, with the low at -$91000.0 in Q4 2025.
- Historically, Gains from Investment Securities has averaged $3.6 million across 4 years, with a median of $3.2 million in 2023.
- The largest YoY upside for Gains from Investment Securities was 4065.8% in 2025 against a maximum downside of 101.38% in 2025.
- CG Oncology's Gains from Investment Securities stood at $5.5 million in 2023, then climbed by 18.83% to $6.6 million in 2024, then plunged by 101.38% to -$91000.0 in 2025, then soared by 291.21% to $174000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $174000.0 (Q1 2026), -$91000.0 (Q4 2025), and $94624.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | CG Oncology | 5.16 Bn | 5.16 Bn | -1.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 174,000.00 |
| Mar 31, 2026 | 174,000.00 |
| Dec 31, 2025 | -91,000.00 |
| Dec 31, 2025 | -91,000.00 |
| Sep 30, 2025 | 94,624.00 |
| Sep 30, 2025 | 94,624.00 |
| Jun 30, 2025 | 8.96 Mn |
| Jun 30, 2025 | 8.96 Mn |
| Mar 31, 2025 | 859,000.00 |
| Mar 31, 2025 | 859,000.00 |
| Dec 31, 2024 | 6.57 Mn |
| Dec 31, 2024 | 6.57 Mn |
| Sep 30, 2024 | 7.71 Mn |
| Sep 30, 2024 | 7.71 Mn |
| Jun 30, 2024 | 215,179.00 |
| Jun 30, 2024 | 215,179.00 |
| Mar 31, 2024 | 6.00 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 5.53 Mn |
| Dec 31, 2023 | 5.53 Mn |